[go: up one dir, main page]

PE20151995A1 - Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos - Google Patents

Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos

Info

Publication number
PE20151995A1
PE20151995A1 PE2015001346A PE2015001346A PE20151995A1 PE 20151995 A1 PE20151995 A1 PE 20151995A1 PE 2015001346 A PE2015001346 A PE 2015001346A PE 2015001346 A PE2015001346 A PE 2015001346A PE 20151995 A1 PE20151995 A1 PE 20151995A1
Authority
PE
Peru
Prior art keywords
compositions
pyrrolopyrimidine
methods
substitute
treatment
Prior art date
Application number
PE2015001346A
Other languages
English (en)
Inventor
John Boylan
Dan Zhu
Jan Elsner
Paul Erdman
Roy L Harris
Dehua Huang
Brandon Jeffy
Mark A Nagy
Rama K Narla
Yuhong Ning
Raj Raheja
Jennifer Riggs
Dale Robinson
Lida Tehrani
Tam Minh Tran
Shuichan Xu
Andrew Antony Calabrese
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50031611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151995(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of PE20151995A1 publication Critical patent/PE20151995A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan en la presente compuestos de pirrolopirimidina que tienen la siguiente estructura: en donde R1, R2, R3, y L son como se definen en la presente, composiciones que comprenden una cantidad efectiva de un Compuesto de pirrolopirimidina, y metodos para tratar o prevenir el cancer de seno, mas particularmente el cancer de seno triple negativo, que comprenden administrar una cantidad efectiva de tales compuestos de pirrolopirimidina a un sujeto en necesidad de los mismos
PE2015001346A 2013-01-16 2014-01-15 Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos PE20151995A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361753259P 2013-01-16 2013-01-16

Publications (1)

Publication Number Publication Date
PE20151995A1 true PE20151995A1 (es) 2016-01-13

Family

ID=50031611

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001346A PE20151995A1 (es) 2013-01-16 2014-01-15 Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos

Country Status (24)

Country Link
US (3) US9428509B2 (es)
EP (2) EP3202403A1 (es)
JP (1) JP2016505041A (es)
KR (1) KR20150108389A (es)
CN (1) CN105188704B (es)
AR (1) AR094494A1 (es)
AU (1) AU2014207641A1 (es)
BR (1) BR112015016997A2 (es)
CA (1) CA2897985A1 (es)
CL (1) CL2015001990A1 (es)
EA (1) EA201591327A1 (es)
EC (1) ECSP15030799A (es)
ES (1) ES2638179T3 (es)
HK (1) HK1212207A1 (es)
IL (1) IL239901A0 (es)
MX (1) MX2015009209A (es)
NI (1) NI201500094A (es)
NZ (1) NZ630467A (es)
PE (1) PE20151995A1 (es)
PH (1) PH12015501576A1 (es)
SG (1) SG11201505446WA (es)
TW (1) TW201441227A (es)
WO (1) WO2014113429A2 (es)
ZA (1) ZA201505011B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
EA201591327A1 (ru) 2013-01-16 2015-12-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
NZ629796A (en) * 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
US10611765B2 (en) 2014-11-06 2020-04-07 Ohio State Innovation Foundation Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors
AU2016219102B2 (en) 2015-02-13 2020-10-15 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
CN105906630B (zh) * 2015-04-06 2018-10-23 四川百利药业有限责任公司 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
WO2016208595A1 (ja) * 2015-06-22 2016-12-29 小野薬品工業株式会社 Ｂｒｋ阻害化合物
WO2017011720A1 (en) * 2015-07-16 2017-01-19 Signal Pharmaceuticals, Llc Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EP3336090B1 (en) * 2015-08-13 2020-07-22 Beijing Hanmi Pharmaceutical Co., Ltd. Irak4 inhibitor and use thereof
AU2016338639A1 (en) * 2015-10-13 2018-05-10 The Scripps Research Institute Therapeutic targeting of casein kinase 1delta in breast cancer
WO2017079765A1 (en) 2015-11-06 2017-05-11 Samumed, Llc Treatment of osteoarthritis
CN105646496B (zh) * 2016-01-20 2018-07-20 华侨大学 一种7H-吡咯并[2,3-d]嘧啶衍生物、其合成方法及应用
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
MD3464285T2 (ro) 2016-06-01 2023-01-31 Biosplice Therapeutics Inc Procedeu pentru prepararea N-(5-(3-(7-(3-fluorfenil)-3H-imidazo[4,5-c]piridin-2-il)-1H-indazol-5-il)piridin-3-il)-3-metilbutanamidei
CN108727400B (zh) * 2017-05-24 2021-07-09 四川晶华生物科技有限公司 一种治疗肿瘤的化合物
ES2914377T3 (es) * 2017-10-27 2022-06-10 Bayer Ag Derivados novedosos de pirazolo-pirrolo-pirimidin-diona como inhibidor de P2X3
EP3731845A4 (en) * 2017-12-28 2021-10-06 Development Center for Biotechnology HETEROCYCLIC COMPOUNDS AS A TYRO3, AXL AND MERTK FAMILY (TAM) OF TYROSINE KINASE RECEPTOR INHIBITORS
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
LT3733673T (lt) 2017-12-28 2022-08-10 Daewoong Pharmaceutical Co., Ltd. Oksi-fluorpiperidino darinys, kaip kinazės inhibitorius
UA125551C2 (uk) * 2018-05-15 2022-04-13 Юніверсіті Оф Теннессі Рісерч Фаундейшн Спосіб лікування тричі негативного раку молочної залози або раку яєчника
US20230000842A1 (en) 2019-01-17 2023-01-05 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
AU2022265032A1 (en) * 2021-04-30 2023-11-16 Wigen Biomedicine Technology (shanghai) Co., Ltd. Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof
EP4335441B1 (en) * 2021-05-03 2025-05-28 JBKLAB Co., Ltd. Pharmaceutical composition for preventing, alleviating, or treating cancer, containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7h-pyrrolo[2,3-d]pyrimidin-5-yl)phenol as active ingredient
TW202330533A (zh) * 2021-10-12 2023-08-01 美商生物銜接醫療公司 7h-吡咯并[2,3-d]嘧啶及其製備及用途

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
US3567725A (en) 1968-11-20 1971-03-02 Merck & Co Inc Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
US4294837A (en) 1980-03-28 1981-10-13 Sterling Drug Inc. 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
US4317909A (en) 1980-03-24 1982-03-02 Sterling Drug Inc. Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
US4294836A (en) 1980-03-24 1981-10-13 Sterling Drug Inc. 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
US4309537A (en) 1980-03-28 1982-01-05 Sterling Drug Inc. Production of imidazo[4,5-b]pyridin-2-ones or thiones
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
JPS63275582A (ja) 1987-05-02 1988-11-14 Naade Kenkyusho:Kk ２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法
DD262026A1 (de) 1987-07-10 1988-11-16 Akad Wissenschaften Ddr Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
US4963561A (en) 1990-02-28 1990-10-16 Sterling Drug Inc. Imidazopyridines, their preparation and use
TW274550B (es) 1992-09-26 1996-04-21 Hoechst Ag
DE19601627A1 (de) 1996-01-18 1997-07-24 Bayer Ag Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
US6031105A (en) 1996-04-09 2000-02-29 Pfizer Inc Substituted pyridines
PL191618B1 (pl) 1997-09-26 2006-06-30 Zentaris Gmbh Związki azabenzimidazolowe, środki farmaceutyczne zawierające te związki, sposób wytwarzania i zastosowania tych związków
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
JP2003146987A (ja) 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
JP3814125B2 (ja) 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
JP2002100363A (ja) 2000-09-25 2002-04-05 Mitsubishi Chemicals Corp リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
JP2002167387A (ja) 2000-11-29 2002-06-11 Dainippon Pharmaceut Co Ltd ２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体
US6566367B2 (en) 2000-12-12 2003-05-20 Pfizer Inc. Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
EP1427730B1 (de) 2001-09-04 2006-07-12 Boehringer Ingelheim Pharma GmbH & Co.KG Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
EP1438048A1 (en) 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
US7247621B2 (en) 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
CN1653077A (zh) 2002-05-06 2005-08-10 健亚生物科技公司 治疗c型肝炎病毒感染的核苷衍生物
US20040204420A1 (en) 2002-08-05 2004-10-14 Rana Tariq M. Compounds for modulating RNA interference
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
ATE433967T1 (de) 2003-01-17 2009-07-15 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
ATE361924T1 (de) 2003-02-26 2007-06-15 Boehringer Ingelheim Pharma Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2004093918A2 (en) 2003-04-23 2004-11-04 Wyeth Holdings Corporation Peg-wortmannin conjugates
CA2734052A1 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
CA2529196A1 (en) 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
WO2005120511A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
WO2006001266A1 (ja) 2004-06-23 2006-01-05 Banyu Pharmaceutical Co., Ltd. ２－アリールプリン誘導体の製造方法
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2005289644A1 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
MX2007005159A (es) 2004-10-29 2007-06-26 Tibotec Pharm Ltd Derivados de pirimidina biciclicos inhibidores del vih.
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
SE0403006D0 (sv) 2004-12-09 2004-12-09 Biovitrum Ab New compounds
WO2006065703A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
KR101362621B1 (ko) 2005-02-16 2014-02-13 아스트라제네카 아베 화합물
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
RU2007140903A (ru) 2005-04-05 2009-05-20 Фармакопия, Инк. (Us) Производные пурина и имидазопиридина для иммуносупрессии
US20090281075A1 (en) 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
EP2583970B1 (en) 2006-08-02 2015-10-14 Cytokinetics, Inc. Certain chemical entities, compositions and methods comprising imidazopyrimidines
WO2008030744A2 (en) 2006-09-05 2008-03-13 Board Of Regents, The University Of Texas System Inhibitors of c-met and uses thereof
WO2008079460A2 (en) 2006-09-05 2008-07-03 Emory University Tyrosine kinase inhibitors for prevention or treatment of infection
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
ES2631003T3 (es) 2006-10-19 2017-08-25 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos
US7968556B2 (en) 2006-10-19 2011-06-28 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2285392A4 (en) 2008-04-11 2012-06-06 Bionovo Inc PROCEDURE AGAINST CANCER WITH EXTRACTS FROM GLEDITSIA SINENSIS LAM
WO2009131687A2 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
AU2009324894B2 (en) 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
KR20120091240A (ko) 2009-10-26 2012-08-17 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물의 합성 및 정제 방법
JP6114554B2 (ja) 2010-02-03 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのｌｋｂ１変異の同定
US20120028972A1 (en) 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
CA2843887A1 (en) 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for lkb1 status
JP5914667B2 (ja) 2011-09-22 2016-05-11 ファイザー・インク ピロロピリミジンおよびプリン誘導体
KR101978537B1 (ko) 2011-10-19 2019-05-14 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제를 사용한 암의 치료
SG10201604558SA (en) 2011-12-02 2016-07-28 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4 methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
JP6114317B2 (ja) 2012-02-24 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法
UA114315C2 (uk) 2012-03-15 2017-05-25 Сігнал Фармасьютікалз, Елелсі Лікування раку інгібіторами тоr-кінази
KR102057358B1 (ko) 2012-03-15 2019-12-18 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제를 사용한 암의 치료
TWI622395B (zh) 2012-03-15 2018-05-01 標誌製藥公司 使用ｔｏｒ之激酶抑制劑之癌症治療
MX361992B (es) 2012-08-06 2018-12-19 Acea Biosciences Inc Compuestos de pirrolopirimidina novedosos como inhibidores de proteínas quinasas.
AU2013202768B2 (en) 2012-10-18 2015-11-05 Signal Pharmaceuticals, Llc Treatment of cancer with TOR kinase inhibitors
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EA201591327A1 (ru) 2013-01-16 2015-12-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений

Also Published As

Publication number Publication date
ECSP15030799A (es) 2015-11-30
NI201500094A (es) 2015-09-21
BR112015016997A2 (pt) 2017-07-11
PH12015501576A1 (en) 2016-02-01
HK1212207A1 (en) 2016-06-10
EP3202403A1 (en) 2017-08-09
CA2897985A1 (en) 2014-07-24
EP2945636A2 (en) 2015-11-25
NZ630467A (en) 2017-02-24
AU2014207641A1 (en) 2015-08-06
IL239901A0 (en) 2015-08-31
ZA201505011B (en) 2016-11-30
KR20150108389A (ko) 2015-09-25
WO2014113429A2 (en) 2014-07-24
TW201441227A (zh) 2014-11-01
EP2945636B1 (en) 2017-06-28
AR094494A1 (es) 2015-08-05
US9346812B2 (en) 2016-05-24
CL2015001990A1 (es) 2016-01-22
SG11201505446WA (en) 2015-08-28
CN105188704B (zh) 2017-09-19
US9795607B2 (en) 2017-10-24
US20140200206A1 (en) 2014-07-17
WO2014113429A3 (en) 2014-10-09
ES2638179T3 (es) 2017-10-19
US20160324861A1 (en) 2016-11-10
CN105188704A (zh) 2015-12-23
EA201591327A1 (ru) 2015-12-30
MX2015009209A (es) 2016-03-17
US20140200207A1 (en) 2014-07-17
US9428509B2 (en) 2016-08-30
JP2016505041A (ja) 2016-02-18

Similar Documents

Publication Publication Date Title
PE20151995A1 (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CR20150571A (es) Compuestos y composiciones terapéuticos
GT201400187A (es) Derivados macrocíclicos para el tratamiento de enfermedades
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
GT201500051A (es) Inhibidores de glucosilceramida sintasa
MX2016001236A (es) Anticuerpos anti-fgfr2iiib afucosilados.
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
BR112015011830A2 (pt) compostos e seus métodos de utilização
AR087918A1 (es) Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX369609B (es) Una composición para usarse en el tratamiento de cáncer deficiente en nmt2.
GT201400003A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CR20140367A (es) Inhibidores de iap
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
NI201500172A (es) Composiciones farmacéuticas
DOP2014000221A (es) Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek
CR20160116A (es) Método para tratar onicomicosis con hidroxipropil quitasano

Legal Events

Date Code Title Description
FD Application declared void or lapsed